Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure

Serafino Fazio1, Emiliano A Palmieri, Flora Affuso

  • 1Department of Internal Medicine, Cardiovascular and Immunological Sciences, University Federico II School of Medicine, 80131 Naples, Italy. fazio@unina.it

Insights

Growth hormone (GH) treatment significantly improved exercise capacity and cardiopulmonary function in patients with chronic heart failure (CHF). These findings suggest GH may offer a new therapeutic avenue for managing CHF patients.

Area of Science:

  • Cardiology
  • Endocrinology
  • Exercise Physiology

Background:

  • Growth hormone (GH) has shown beneficial effects in experimental heart failure models.
  • Investigated GH's impact on exercise capacity and cardiopulmonary performance in dilated cardiomyopathy patients with chronic heart failure (CHF).

Purpose of the Study:

  • To evaluate the effects of GH administration on physical exercise capacity and cardiopulmonary performance in patients with chronic heart failure (CHF).

Main Methods:

  • A randomized, double-blind trial involving 22 CHF patients (NYHA class II-III).
  • Patients received either GH (4 IU sc every other day) or placebo for 3 months.
  • Spirometry and symptom-limited cardiopulmonary exercise testing were performed before and after treatment.

Main Results:

  • GH treatment increased IGF-I levels and improved NYHA functional class, exercise duration, peak power output, peak oxygen consumption, and anaerobic threshold.
  • GH also improved ventilatory efficiency and chronotropic index without altering lung function.
  • Placebo group showed no significant improvements.

Conclusions:

  • GH administration enhanced physical exercise capacity and cardiopulmonary performance in CHF patients.
  • These findings provide insights into potential mechanisms of GH's benefit in CHF.
  • GH may represent a novel therapeutic strategy for improving outcomes in CHF.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Exercise and Cardiac Output01:17

Exercise and Cardiac Output

Regular physical activity is essential for maintaining cardiovascular health, with aerobic exercises being particularly effective. According to the American Heart Association, 150 minutes of moderate to intense aerobic exercise per week is recommended for a healthy heart. Aerobic activities may include brisk walking, running, bicycling, cross-country skiing, and swimming, ideally performed three to five times per week.
Sustained exercise increases the muscles' oxygen demand, which can be met...